PT  - JOURNAL ARTICLE
AU  - Parry, Nicola
ED  - Sonnenblick, Amir
TI  - Docetaxel Added to Anthracycline Regimens Benefits Patients with Highly Proliferative ER-Positive Breast Cancer
DP  - 2014 Dec 01
TA  - MD Conference Express
PG  - 13--14
VI  - 14
IP  - 36
4099  - http://mdc.sagepub.com/content/14/36/13.short
4100  - http://mdc.sagepub.com/content/14/36/13.full
AB  - Adding taxanes to an anthracycline-based chemotherapy regimen in the adjuvant setting has become a standard approach in the management of patients with breast cancer. However, long-term outcomes data are still lacking regarding the safety and efficacy of this approach. This article presents data from the 10-year final safety and efficacy analyses of the Intergroup Phase 3 BIG 2-98 trial [NCT00174655].